İstanbul escort bayan sivas escort samsun escort bayan sakarya escort Muğla escort Mersin escort Escort malatya Escort konya Kocaeli Escort Kayseri Escort izmir escort bayan hatay bayan escort antep Escort bayan eskişehir escort bayan erzurum escort bayan elazığ escort diyarbakır escort escort bayan Çanakkale Bursa Escort bayan Balıkesir escort aydın Escort Antalya Escort ankara bayan escort Adana Escort bayan

Thursday, February 22, 2024
Home Health Inflammatory Bowel Disease: A Prime Time for New Drug Development!

Inflammatory Bowel Disease: A Prime Time for New Drug Development!

IBD is a chronic, idiopathic, inflammatory disease of the digestive tract, including two phenotypes: ulcerative colitis (UC) and Crohn’s disease (CD). UC patients may experience symptoms such as bloody diarrhea, inflammation, and ulceration limited to the mucosal layer of the colon[1], while CD patients may exhibit chronic inflammatory responses throughout the digestive tract, leading to stenosis, fistulae, and intestinal obstruction.

Treatment

IBD cannot be cured, but treatments can ease symptoms and improve quality of life. Treatment options include drug therapy such as anti-inflammatory drugs, immunosuppressants, and biologics, as well as surgical resection of damaged or diseased portions of the digestive tract[2]. However, some individuals do not respond well to these treatments. Researchers have been developing new biological therapies that target key steps in known immune pathways, such as natalizumab and risankizumab. But there are still challenges, such as the risks associated with immunosuppressive therapies and individual differences in how patients respond to medication. The concept of precision medicine needs to be introduced, which further stimulates the development of more innovative drugs.

GemPharmatech‘s IBD models

Choosing the appropriate animal model for studying a new drug is a crucial first step. GemPharmatech has developed several animal models of inflammatory bowel disease (IBD), including induced models and genetically modified models of spontaneous colitis, which will aid in preclinical medication evaluation and mechanism studies.

DNBS-Induced CD models

 

 

  • Aminosalicylic acid effectively alleviates DNBS-induced Crohn’s disease

Visitourwebsitetolearnmore: https://en.gempharmatech.com/content/details100032_4489252.html

Refrences:

  1. Ungaro, R., et al., Ulcerative colitis. Lancet, 2017. 389: p. 1756-1770.
  2. https://www.mayoclinic.org/diseases-conditions/inflammatory-bowel-disease/diagnosis-treatment/drc-20353320

Most Popular

Next-Gen Trading: Harnessing CFDs for Energy Markets

In the ever-evolving financial market landscape, traders continually seek innovative avenues to capitalize on opportunities. One such avenue that has gained significant traction in...

The Art of Budget-Friendly Home Décor: Transforming Spaces with Watkins-Rosaline Finds

In an era where the appreciation for budget-friendly home décor is soaring, the art of transforming spaces with unique finds has become an enchanting...

Unlocking the Power of Email Marketing: Your Go-To Guide for Marketing Companies in Essex

In the bustling world of digital marketing, standing out from the crowd is essential for success. Email marketing emerges as a powerful tool for...

Luxury Redefined: Discover High-Quality Bra Panty Sets in UAE

In the ever-evolving world of fashion, luxury undergoes constant redefinition. From opulent fabrics to exquisite craftsmanship, the definition of luxury extends beyond mere material...

A Detailed Discussion on Custom Home Builders

Are you interested in making your home unique and stylish in your look? You must select the best ideas for your home to bring...

Understanding the Art of Strategizing Your Bets on BetBhai9

Betbhai9, Laser247, Sky247 Login is not just your average online betting platform; it is a world of possibilities waiting to be explored. With its...